DeepSight Technology

DeepSight Technology is a private, pre-revenue medical device innovator founded in 2017 and based in Menlo Park, California. The company is developing a proprietary sensor platform, NeedleVue™, designed to be integrated into interventional instruments to provide sub-millimeter, real-time tracking and imaging directly from the instrument tip, using only ultrasound. This technology targets a vast market of over 200 million annual needle-based procedures, aiming to improve accuracy, reduce procedure times and radiation exposure, and address the shortage of specialized practitioners across numerous clinical areas including biopsies, tumor ablation, and structural heart repair.

NeedleVue™ and OnPoint™ sensor technologies that integrate into interventional instruments (needles, wires, catheters) to provide real-time, sub-millimeter ultrasound imaging and tracking directly from the instrument tip.

DeepSight competes with existing interventional imaging modalities like fluoroscopy, conventional ultrasound with guides, and electromagnetic tracking systems. It also faces potential competition from other startups and large medtech companies developing advanced guidance solutions. Its claimed differentiators are sub-millimeter accuracy, a non-electrical/no-calibration design, and tip-based ultrasound imaging.